Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 263

1.

Brain Lewy-Type Synucleinopathy Density Is Associated with a Lower Prevalence of Atherosclerotic Cardiovascular Disease Risk Factors in Patients with Parkinson's Disease1.

Driver-Dunckley ED, Zhang N, Adler CH, Serrano GE, Sue LI, Shill HA, Mehta SH, Belden CM, Zamrini EY, Davis K, Beach TG.

J Parkinsons Dis. 2019 Jul 4. doi: 10.3233/JPD-191610. [Epub ahead of print]

PMID:
31282425
2.

Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease.

Malek-Ahmadi M, Beach TG, Zamrini E, Adler CH, Sabbagh MN, Shill HA, Jacobson SA, Belden CM, Caselli RJ, Woodruff BK, Rapscak SZ, Ahern GL, Shi J, Caviness JN, Driver-Dunckley E, Mehta SH, Shprecher DR, Spann BM, Tariot P, Davis KJ, Long KE, Nicholson LR, Intorcia A, Glass MJ, Walker JE, Callan M, Curry J, Cutler B, Oliver J, Arce R, Walker DG, Lue LF, Serrano GE, Sue LI, Chen K, Reiman EM.

PLoS One. 2019 Jun 25;14(6):e0217566. doi: 10.1371/journal.pone.0217566. eCollection 2019.

3.

Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.

Black KJ, Nasrallah H, Isaacson S, Stacy M, Pahwa R, Adler CH, Alva G, Cooney JW, Kremens D, Menza MA, Meyer JM, Patkar AA, Simuni T, Morrissette DA, Stahl SM.

CNS Spectr. 2019 Jun 11:1-2. doi: 10.1017/S1092852919000932. [Epub ahead of print] No abstract available.

PMID:
31182180
4.

Regional neuropathology distribution and verbal fluency impairments in Parkinson's disease.

El-Nazer R, Adler CH, Beach TG, Belden CM, Artz J, Shill HA, Driver-Dunckley E, Mehta SH, Sabbagh MN, Serrano GE, Sue LI, Zamrini E, Benge JF.

Parkinsonism Relat Disord. 2019 May 10. pii: S1353-8020(19)30235-4. doi: 10.1016/j.parkreldis.2019.05.014. [Epub ahead of print]

PMID:
31109728
5.

Tau Positron-Emission Tomography in Former National Football League Players.

Stern RA, Adler CH, Chen K, Navitsky M, Luo J, Dodick DW, Alosco ML, Tripodis Y, Goradia DD, Martin B, Mastroeni D, Fritts NG, Jarnagin J, Devous MD Sr, Mintun MA, Pontecorvo MJ, Shenton ME, Reiman EM.

N Engl J Med. 2019 May 2;380(18):1716-1725. doi: 10.1056/NEJMoa1900757. Epub 2019 Apr 10.

PMID:
30969506
6.

Risk of Parkinson's disease dementia related to level I MDS PD-MCI.

Hoogland J, Boel JA, de Bie RMA, Schmand BA, Geskus RB, Dalrymple-Alford JC, Marras C, Adler CH, Weintraub D, Junque C, Pedersen KF, Mollenhauer B, Goldman JG, Tröster AI, Burn DJ, Litvan I, Geurtsen GJ; MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”.

Mov Disord. 2019 Mar;34(3):430-435. doi: 10.1002/mds.27617. Epub 2019 Jan 17.

PMID:
30653248
7.

Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.

Black KJ, Nasrallah H, Isaacson S, Stacy M, Pahwa R, Adler CH, Alva G, Cooney JW, Kremens D, Menza MA, Meyer JM, Patkar AA, Simuni T, Morrissette DA, Stahl SM.

CNS Spectr. 2018 Dec;23(6):402-413. doi: 10.1017/S1092852918001359.

PMID:
30588905
8.

Tau immunoreactivity in peripheral tissues of human aging and select tauopathies.

Dugger BN, Hoffman BR, Scroggins A, Serrano GE, Adler CH, Shill HA, Belden CM, Sabbagh MN, Caviness JN, Driver Dunckley E, Beach TG.

Neurosci Lett. 2019 Mar 23;696:132-139. doi: 10.1016/j.neulet.2018.12.031. Epub 2018 Dec 21.

PMID:
30579993
9.

Publisher Correction: Enhancers active in dopamine neurons are a primary link between genetic variation and neuropsychiatric disease.

Dong X, Liao Z, Gritsch D, Hadzhiev Y, Bai Y, Locascio JJ, Guennewig B, Liu G, Blauwendraat C, Wang T, Adler CH, Hedreen JC, Faull RLM, Frosch MP, Nelson PT, Rizzu P, Cooper AA, Heutink P, Beach TG, Mattick JS, Müller F, Scherzer CR.

Nat Neurosci. 2019 Jan;22(1):144-147. doi: 10.1038/s41593-018-0277-z.

PMID:
30482917
10.

Are Clinical Certainty Ratings Helpful in the Diagnosis of Parkinson's Disease?

Gupta HV, Mehta SH, Zhang N, Hentz JG, Shill HA, Driver-Dunckley E, Sabbagh MN, Belden CM, Dugger BN, Beach TG, Serrano GE, Sue LI, Davis K, Adler CH.

Mov Disord Clin Pract. 2018 Feb 22;5(2):165-170. doi: 10.1002/mdc3.12589. eCollection 2018 Mar-Apr.

11.

Importance of low diagnostic Accuracy for early Parkinson's disease.

Beach TG, Adler CH.

Mov Disord. 2018 Oct;33(10):1551-1554. doi: 10.1002/mds.27485. Epub 2018 Oct 4. No abstract available.

PMID:
30288780
12.

Feasibility and Safety of Multicenter Tissue and Biofluid Sampling for α-Synuclein in Parkinson's Disease: The Systemic Synuclein Sampling Study (S4).

Chahine LM, Beach TG, Seedorff N, Caspell-Garcia C, Coffey CS, Brumm M, Adler CH, Serrano GE, Linder C, Mosovsky S, Foroud T, Riss H, Ecklund D, Seibyl J, Jennings D, Arnedo V, Riley L, Dave KD, Mollenhauer B; Systemic sSynuclein Sampling study.

J Parkinsons Dis. 2018;8(4):517-527. doi: 10.3233/JPD-181434.

13.

Lewy body pathology in Alzheimer's disease: A clinicopathological prospective study.

Savica R, Beach TG, Hentz JG, Sabbagh MN, Serrano GE, Sue LI, Dugger BN, Shill HA, Driver-Dunckley E, Caviness JN, Mehta SH, Jacobson SA, Belden CM, Davis KJ, Zamrini E, Shprecher DR, Adler CH.

Acta Neurol Scand. 2019 Jan;139(1):76-81. doi: 10.1111/ane.13028. Epub 2018 Oct 7.

14.

Enhancers active in dopamine neurons are a primary link between genetic variation and neuropsychiatric disease.

Dong X, Liao Z, Gritsch D, Hadzhiev Y, Bai Y, Locascio JJ, Guennewig B, Liu G, Blauwendraat C, Wang T, Adler CH, Hedreen JC, Faull RLM, Frosch MP, Nelson PT, Rizzu P, Cooper AA, Heutink P, Beach TG, Mattick JS, Müller F, Scherzer CR.

Nat Neurosci. 2018 Oct;21(10):1482-1492. doi: 10.1038/s41593-018-0223-0. Epub 2018 Sep 17. Erratum in: Nat Neurosci. 2019 Jan;22(1):144-147.

15.

Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests.

Hoogland J, van Wanrooij LL, Boel JA, Goldman JG, Stebbins GT, Dalrymple-Alford JC, Marras C, Adler CH, Junque C, Pedersen KF, Mollenhauer B, Zabetian CP, Eslinger PJ, Lewis SJG, Wu RM, Klein M, Rodriguez-Oroz MC, Cammisuli DM, Barone P, Biundo R, de Bie RMA, Schmand BA, Tröster AI, Burn DJ, Litvan I, Filoteo JV, Geurtsen GJ, Weintraub D; IPMDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”.

Mov Disord. 2018 Nov;33(11):1750-1759. doi: 10.1002/mds.110. Epub 2018 Sep 14.

PMID:
30216541
16.

Degeneration of human photosensitive retinal ganglion cells may explain sleep and circadian rhythms disorders in Parkinson's disease.

Ortuño-Lizarán I, Esquiva G, Beach TG, Serrano GE, Adler CH, Lax P, Cuenca N.

Acta Neuropathol Commun. 2018 Sep 10;6(1):90. doi: 10.1186/s40478-018-0596-z.

17.

Weight Loss in Parkinson's Disease: No Evidence for Role of Small Intestinal Bacterial Overgrowth.

DiBaise JK, Crowell MD, Driver-Dunckley E, Mehta SH, Hoffman-Snyder C, Lin T, Adler CH.

J Parkinsons Dis. 2018;8(4):571-581. doi: 10.3233/JPD-181386.

PMID:
30149465
18.

Movement disorder society criteria for clinically established early Parkinson's disease.

Berg D, Adler CH, Bloem BR, Chan P, Gasser T, Goetz CG, Halliday G, Lang AE, Lewis S, Li Y, Liepelt-Scarfone I, Litvan I, Marek K, Maetzler C, Mi T, Obeso J, Oertel W, Olanow CW, Poewe W, Rios-Romenets S, Schäffer E, Seppi K, Heim B, Slow E, Stern M, Bledsoe IO, Deuschl G, Postuma RB.

Mov Disord. 2018 Oct;33(10):1643-1646. doi: 10.1002/mds.27431. Epub 2018 Aug 25.

PMID:
30145841
19.

Characterization of the symptoms of neurogenic orthostatic hypotension and their impact from a survey of patients and caregivers.

Claassen DO, Adler CH, Hewitt LA, Gibbons C.

BMC Neurol. 2018 Aug 25;18(1):125. doi: 10.1186/s12883-018-1129-x.

20.

Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4).

Beach TG, Serrano GE, Kremer T, Canamero M, Dziadek S, Sade H, Derkinderen P, Corbillé AG, Letournel F, Munoz DG, White CL 3rd, Schneider J, Crary JF, Sue LI, Adler CH, Glass MJ, Intorcia AJ, Walker JE, Foroud T, Coffey CS, Ecklund D, Riss H, Goßmann J, König F, Kopil CM, Arnedo V, Riley L, Linder C, Dave KD, Jennings D, Seibyl J, Mollenhauer B, Chahine L; Systemic Synuclein Sampling Study (S4) .

J Neuropathol Exp Neurol. 2018 Sep 1;77(9):793-802. doi: 10.1093/jnen/nly056.

PMID:
30107604
21.

Consensus-Based Attributes for Identifying Patients With Spasmodic Dysphonia and Other Voice Disorders.

Ludlow CL, Domangue R, Sharma D, Jinnah HA, Perlmutter JS, Berke G, Sapienza C, Smith ME, Blumin JH, Kalata CE, Blindauer K, Johns M, Hapner E, Harmon A, Paniello R, Adler CH, Crujido L, Lott DG, Bansberg SF, Barone N, Drulia T, Stebbins G.

JAMA Otolaryngol Head Neck Surg. 2018 Aug 1;144(8):657-665. doi: 10.1001/jamaoto.2018.0644.

22.

The Yips: Methods to Identify Golfers with a Dystonic Etiology/Golfer's Cramp.

Adler CH, Temkit M, Crews D, McDaniel T, Tucker J, Hentz JG, Marquardt C, Abraham D, Caviness JN.

Med Sci Sports Exerc. 2018 Nov;50(11):2226-2230. doi: 10.1249/MSS.0000000000001687.

PMID:
29889820
23.

Essential tremor and depression.

Aslam S, Zhang N, Adler CH, Caviness JN, Driver-Dunckley E, Mehta SH, Sabbagh MN, Belden C, Zamrini E, Beach TG, Shill HA.

Mov Disord Clin Pract. 2017 Nov-Dec;4(6):838-842. doi: 10.1002/mdc3.12530. Epub 2017 Jul 17.

24.

Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open-label ADS-5102.

Isaacson SH, Fahn S, Pahwa R, Tanner CM, Espay AJ, Trenkwalder C, Adler CH, Patni R, Johnson R.

Mov Disord Clin Pract. 2018 Mar-Apr;5(2):183-190. doi: 10.1002/mdc3.12595. Epub 2018 Feb 23.

25.

Predicting alpha-synuclein pathology by REM sleep behavior disorder diagnosis.

Shprecher DR, Adler CH, Zhang N, Hentz JG, Serrano GE, Dugger BN, Shill HA, Savica R, Caviness JN, Sabbagh MN, Belden CM, Driver-Dunckley E, Mehta SH, Sue LI, Davis KJ, Zamrini E, Beach TG.

Parkinsonism Relat Disord. 2018 Oct;55:92-96. doi: 10.1016/j.parkreldis.2018.05.020. Epub 2018 May 17.

PMID:
29779682
26.

Phosphorylated α-synuclein in the retina is a biomarker of Parkinson's disease pathology severity.

Ortuño-Lizarán I, Beach TG, Serrano GE, Walker DG, Adler CH, Cuenca N.

Mov Disord. 2018 Aug;33(8):1315-1324. doi: 10.1002/mds.27392. Epub 2018 May 8.

PMID:
29737566
27.

Probing the striatal dopamine system for a putative neuroprotective effect of deep brain stimulation in Parkinson's disease.

Pal G, Ouyang B, Verhagen L, Serrano G, Shill HA, Adler CH, Beach TG, Kordower JH; AZSAND.

Mov Disord. 2018 Apr;33(4):652-654. doi: 10.1002/mds.27280. Epub 2018 Jan 30. No abstract available.

28.

Protein Phosphatase 2A and Its Methylation Modulating Enzymes LCMT-1 and PME-1 Are Dysregulated in Tauopathies of Progressive Supranuclear Palsy and Alzheimer Disease.

Park HJ, Lee KW, Oh S, Yan R, Zhang J, Beach TG, Adler CH, Voronkov M, Braithwaite SP, Stock JB, Mouradian MM.

J Neuropathol Exp Neurol. 2018 Feb 1;77(2):139-148. doi: 10.1093/jnen/nlx110.

29.

Association Between Pathology and Electroencephalographic Activity in Parkinson's Disease.

Caviness JN, Beach TG, Hentz JG, Shill HA, Driver-Dunckley ED, Adler CH.

Clin EEG Neurosci. 2018 Sep;49(5):321-327. doi: 10.1177/1550059417696179. Epub 2017 Feb 1.

PMID:
29161906
30.

Improved diagnosis of Parkinson's disease from a detailed olfactory phenotype.

Gerkin RC, Adler CH, Hentz JG, Shill HA, Driver-Dunckley E, Mehta SH, Sabbagh MN, Caviness JN, Dugger BN, Serrano G, Belden C, Smith BH, Sue L, Davis KJ, Zamrini E, Beach TG.

Ann Clin Transl Neurol. 2017 Sep 8;4(10):714-721. doi: 10.1002/acn3.447. eCollection 2017 Oct.

31.

Does Parkinson's disease start in the gut?

Lionnet A, Leclair-Visonneau L, Neunlist M, Murayama S, Takao M, Adler CH, Derkinderen P, Beach TG.

Acta Neuropathol. 2018 Jan;135(1):1-12. doi: 10.1007/s00401-017-1777-8. Epub 2017 Oct 16. Review.

PMID:
29039141
32.

Spasmodic Dysphonia: A Review. Part 1: Pathogenic Factors.

Hintze JM, Ludlow CL, Bansberg SF, Adler CH, Lott DG.

Otolaryngol Head Neck Surg. 2017 Oct;157(4):551-557. doi: 10.1177/0194599817728521. Epub 2017 Aug 29. Review.

PMID:
28850801
33.

Spasmodic Dysphonia: A Review. Part 2: Characterization of Pathophysiology.

Hintze JM, Ludlow CL, Bansberg SF, Adler CH, Lott DG.

Otolaryngol Head Neck Surg. 2017 Oct;157(4):558-564. doi: 10.1177/0194599817728465. Epub 2017 Aug 29. Review.

PMID:
28850796
34.

GBA mutations in Parkinson disease: earlier death but similar neuropathological features.

Adler CH, Beach TG, Shill HA, Caviness JN, Driver-Dunckley E, Sabbagh MN, Patel A, Sue LI, Serrano G, Jacobson SA, Davis K, Belden CM, Dugger BN, Paciga SA, Winslow AR, Hirst WD, Hentz JG.

Eur J Neurol. 2017 Nov;24(11):1363-1368. doi: 10.1111/ene.13395. Epub 2017 Aug 17.

35.

Mild cognitive impairment as a risk factor for Parkinson's disease dementia.

Hoogland J, Boel JA, de Bie RMA, Geskus RB, Schmand BA, Dalrymple-Alford JC, Marras C, Adler CH, Goldman JG, Tröster AI, Burn DJ, Litvan I, Geurtsen GJ; MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”.

Mov Disord. 2017 Jul;32(7):1056-1065. doi: 10.1002/mds.27002. Epub 2017 Jun 12.

36.

Peripheral synucleinopathy in early Parkinson's disease: Submandibular gland needle biopsy findings.

Adler CH, Dugger BN, Hentz JG, Hinni ML, Lott DG, Driver-Dunckley E, Mehta S, Serrano G, Sue LI, Duffy A, Intorcia A, Filon J, Pullen J, Walker DG, Beach TG.

Mov Disord. 2017 May;32(5):722-723. doi: 10.1002/mds.27044. No abstract available.

PMID:
28513078
37.

Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry.

Trosch RM, Espay AJ, Truong D, Gil R, Singer C, LeWitt PA, Lew MF, Tagliati M, Adler CH, Chen JJ, Marchese D, Comella CL.

J Neurol Sci. 2017 May 15;376:84-90. doi: 10.1016/j.jns.2017.02.042. Epub 2017 Feb 21.

38.

Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimer's pathology not α-synuclein pathology.

Walker DG, Lue LF, Tang TM, Adler CH, Caviness JN, Sabbagh MN, Serrano GE, Sue LI, Beach TG.

Neurobiol Aging. 2017 Jun;54:175-186. doi: 10.1016/j.neurobiolaging.2017.03.007. Epub 2017 Mar 16.

39.

The Systemic Synuclein Sampling Study: toward a biomarker for Parkinson's disease.

Visanji NP, Mollenhauer B, Beach TG, Adler CH, Coffey CS, Kopil CM, Dave KD, Foroud T, Chahine L, Jennings D; Systemic Synuclein Sampling Study (S4).

Biomark Med. 2017 Apr;11(4):359-368. doi: 10.2217/bmm-2016-0366. Epub 2017 Mar 29.

40.

The association between vertebrobasilar dolichoectasia and hemifacial spasm: Historical perspective.

Adler CH.

Parkinsonism Relat Disord. 2017 May;38:97. doi: 10.1016/j.parkreldis.2017.02.023. Epub 2017 Feb 22. No abstract available.

PMID:
28274678
41.

Factors associated with healthcare-related frustrations among adults with chronic conditions.

Smith ML, Bergeron CD, Adler CH, Patel A, Ahn S, Towne SD Jr, Bien M, Ory MG.

Patient Educ Couns. 2017 Jun;100(6):1185-1193. doi: 10.1016/j.pec.2016.12.033. Epub 2017 Jan 6.

PMID:
28117194
42.

The Search for a Peripheral Biopsy Indicator of α-Synuclein Pathology for Parkinson Disease.

Lee JM, Derkinderen P, Kordower JH, Freeman R, Munoz DG, Kremer T, Zago W, Hutten SJ, Adler CH, Serrano GE, Beach TG.

J Neuropathol Exp Neurol. 2017 Jan 1;76(1):2-15. doi: 10.1093/jnen/nlw103. Review.

PMID:
28069931
43.

Comparison of neuropathology in Parkinson's disease subjects with and without deep brain stimulation.

Pal GD, Ouyang B, Serrano G, Shill HA, Goetz C, Stebbins G, Metman LV, Driver-Dunckley E, Mehta SH, Caviness JN, Sabbagh MN, Adler CH, Beach TG; Arizona Study of Aging Neurodegenerative Disorders.

Mov Disord. 2017 Feb;32(2):274-277. doi: 10.1002/mds.26882. Epub 2016 Dec 2.

PMID:
27911008
44.

Impact of Cervical Dystonia on Work Productivity: An Analysis From a Patient Registry.

Molho ES, Stacy M, Gillard P, Charles D, Adler CH, Jankovic J, Schwartz M, Brin MF.

Mov Disord Clin Pract. 2016 Mar-Apr;3(2):130-138. Epub 2015 Dec 16.

45.

Knowledge gaps and research recommendations for essential tremor.

Hopfner F, Haubenberger D, Galpern WR, Gwinn K, Van't Veer A, White S, Bhatia K, Adler CH, Eidelberg D, Ondo W, Stebbins GT, Tanner CM, Helmich RC, Lenz FA, Sillitoe RV, Vaillancourt D, Vitek JL, Louis ED, Shill HA, Frosch MP, Foroud T, Kuhlenbäumer G, Singleton A, Testa CM, Hallett M, Elble R, Deuschl G.

Parkinsonism Relat Disord. 2016 Dec;33:27-35. doi: 10.1016/j.parkreldis.2016.10.002. Epub 2016 Oct 4. Review.

46.

Multicenter Assessment of Immunohistochemical Methods for Pathological Alpha-Synuclein in Sigmoid Colon of Autopsied Parkinson's Disease and Control Subjects.

Beach TG, Corbillé AG, Letournel F, Kordower JH, Kremer T, Munoz DG, Intorcia A, Hentz J, Adler CH, Sue LI, Walker J, Serrano G, Derkinderen P.

J Parkinsons Dis. 2016 Oct 19;6(4):761-770.

47.

Dysregulation of protein phosphatase 2A in parkinson disease and dementia with lewy bodies.

Park HJ, Lee KW, Park ES, Oh S, Yan R, Zhang J, Beach TG, Adler CH, Voronkov M, Braithwaite SP, Stock JB, Mouradian MM.

Ann Clin Transl Neurol. 2016 Sep 7;3(10):769-780. eCollection 2016 Oct.

48.

Abolishing the 1-year rule: How much evidence will be enough?

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G.

Mov Disord. 2016 Nov;31(11):1623-1627. doi: 10.1002/mds.26796. Epub 2016 Sep 26. No abstract available.

PMID:
27666574
49.

The new definition and diagnostic criteria of Parkinson's disease.

Postuma RB, Berg D, Adler CH, Bloem BR, Chan P, Deuschl G, Gasser T, Goetz CG, Halliday G, Joseph L, Lang AE, Liepelt-Scarfone I, Litvan I, Marek K, Oertel W, Olanow CW, Poewe W, Stern M.

Lancet Neurol. 2016 May;15(6):546-8. doi: 10.1016/S1474-4422(16)00116-2. Epub 2016 Apr 11. No abstract available.

PMID:
27302120
50.

Gender Differences in Alzheimer Disease: Brain Atrophy, Histopathology Burden, and Cognition.

Filon JR, Intorcia AJ, Sue LI, Vazquez Arreola E, Wilson J, Davis KJ, Sabbagh MN, Belden CM, Caselli RJ, Adler CH, Woodruff BK, Rapscak SZ, Ahern GL, Burke AD, Jacobson S, Shill HA, Driver-Dunckley E, Chen K, Reiman EM, Beach TG, Serrano GE.

J Neuropathol Exp Neurol. 2016 Jun 12. pii: nlw047. [Epub ahead of print]

PMID:
27297671

Supplemental Content

Loading ...
Support Center